These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

603 related items for PubMed ID: 9619801

  • 1. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V, Stürmer M, Staszewski S, Gröschel B, Hertogs K, de Béthune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD, Larder BA.
    AIDS; 1998 May 07; 12(7):705-12. PubMed ID: 9619801
    [Abstract] [Full Text] [Related]

  • 2. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S, La Seta Catamancio S, Sheridan F, Parker D.
    J Clin Virol; 2000 Dec 07; 19(3):135-42. PubMed ID: 11090748
    [Abstract] [Full Text] [Related]

  • 3. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B, Leal M.
    AIDS; 1998 Jun 18; 12(9):1015-20. PubMed ID: 9662197
    [Abstract] [Full Text] [Related]

  • 4. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
    Picard V, Angelini E, Maillard A, Race E, Clavel F, Chêne G, Ferchal F, Molina JM.
    J Infect Dis; 2001 Sep 15; 184(6):781-4. PubMed ID: 11517441
    [Abstract] [Full Text] [Related]

  • 5. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V, Larder BA.
    Antivir Ther; 2001 Sep 15; 6 Suppl 3():25-44. PubMed ID: 11678471
    [Abstract] [Full Text] [Related]

  • 6. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
    Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G, Tisdale M.
    AIDS; 2000 Jan 28; 14(2):163-71. PubMed ID: 10708287
    [Abstract] [Full Text] [Related]

  • 7. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.
    J Med Virol; 1999 Dec 28; 59(4):507-11. PubMed ID: 10534734
    [Abstract] [Full Text] [Related]

  • 8. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, Emery S, Cooper D, Lange J, Phanuphak P.
    AIDS; 2003 Sep 05; 17(13):1889-96. PubMed ID: 12960821
    [Abstract] [Full Text] [Related]

  • 9. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
    Ait-Khaled M, Rakik A, Griffin P, Cutrell A, Fischl MA, Clumeck N, Greenberg SB, Rubio R, Peters BS, Pulido F, Gould J, Pearce G, Spreen W, Tisdale M, Lafon S, CNA3003 International Study Team.
    Antivir Ther; 2002 Mar 05; 7(1):43-51. PubMed ID: 12008787
    [Abstract] [Full Text] [Related]

  • 10. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
    Barnas D, Koontz D, Bazmi H, Bixby C, Jemsek J, Mellors JW.
    Antivir Ther; 2010 Mar 05; 15(3):437-41. PubMed ID: 20516563
    [Abstract] [Full Text] [Related]

  • 11. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
    de Jong JJ, Goudsmit J, Lukashov VV, Hillebrand ME, Baan E, Huismans R, Danner SA, ten Veen JH, de Wolf F, Jurriaans S.
    AIDS; 1999 Jan 14; 13(1):75-80. PubMed ID: 10207547
    [Abstract] [Full Text] [Related]

  • 12. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.
    Antivir Chem Chemother; 2000 Jul 14; 11(4):291-301. PubMed ID: 10950391
    [Abstract] [Full Text] [Related]

  • 13. Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
    Bradshaw D, Malik S, Booth C, Van Houtte M, Pattery T, Waters A, Ainsworth J, Geretti AM.
    Antimicrob Agents Chemother; 2007 Dec 14; 51(12):4489-91. PubMed ID: 17876005
    [Abstract] [Full Text] [Related]

  • 14. Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.
    Van Laethem K, Witvrouw M, Pannecouque C, Van Remoortel B, Schmit JC, Esnouf R, Kleim JP, Balzarini J, Desmyter J, De Clercq E, Vandamme AM.
    AIDS; 2001 Mar 30; 15(5):553-61. PubMed ID: 11316991
    [Abstract] [Full Text] [Related]

  • 15. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ, Chappey C, Parkin NT, Miller MD.
    Antivir Ther; 2008 Mar 30; 13(2):189-97. PubMed ID: 18505170
    [Abstract] [Full Text] [Related]

  • 16. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors.
    Catucci M, Venturi G, Romano L, Riccio ML, De Milito A, Valensin PE, Zazzi M.
    J Acquir Immune Defic Syndr; 1999 Jul 01; 21(3):203-8. PubMed ID: 10421243
    [Abstract] [Full Text] [Related]

  • 17. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
    Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.
    Antivir Ther; 2007 Jul 01; 12(1):25-30. PubMed ID: 17503744
    [Abstract] [Full Text] [Related]

  • 18. Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
    Pellegrin I, Segondy M, Garrigue I, Izopet J, Montes B, Pellegrin JL, Reynes J, Massip P, Puel J, Fleury H.
    J Acquir Immune Defic Syndr; 2000 Dec 15; 25(5):465-6. PubMed ID: 11141248
    [No Abstract] [Full Text] [Related]

  • 19. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C.
    HIV Med; 2013 Oct 15; 14(9):571-7. PubMed ID: 23668660
    [Abstract] [Full Text] [Related]

  • 20. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
    Parikh UM, Bacheler L, Koontz D, Mellors JW.
    J Virol; 2006 May 15; 80(10):4971-7. PubMed ID: 16641288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.